Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
about
Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines.Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication.Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis.Curcumin protects mice from coxsackievirus B3-induced myocarditis by inhibiting the phosphatidylinositol 3 kinase/Akt/nuclear factor-κB pathway.
P2860
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
@en
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
@nl
type
label
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
@en
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
@nl
prefLabel
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
@en
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
@nl
P2093
P2860
P1476
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
@en
P2093
Andreas Henke
Nadine Jarasch
Peter Wutzler
P2860
P304
P356
10.1586/14760584.7.10.1557
P577
2008-12-01T00:00:00Z